Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT07409181 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07409181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07409181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2026
Completion date
July 8, 2029
Enrollment
405 (estimated)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus